Danaher Corporation (DHR) Fair Value & Analysis
Healthcare · US · Market cap $132B
Danaher Corporation
DHR · US
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Share price +5.5% over the past month.
Price vs Fair Value (12 months)
12‑month range $150.31 – $224.23 · fair‑value band $66.53 – $140.42 · the $178.97 price screens above the $112.34 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Danaher Corporation (DHR) currently trades at $178.97, while our model-based Fair Value estimate is $112.34 — implying the stock looks roughly 37.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Danaher Corporation generated revenue of $24.8B at a net margin of 14.9%. Revenue grew 3.7% year over year. It earns a return on equity of 7.1%. Net debt stands at $13.8B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spect…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Danaher Corporation reported revenue of $24.6B in FY2025 versus $29.5B in FY2021, a compound −4.4%/yr. Reported net income was $3.6B in FY2025, compounding −13.4%/yr from FY2021.
Open the full interactive analysis →
Recent news
- Is Sotera Health Company (SHC) A Good Stock To Buy Now?
- Danaher Foundation Commits $1 Million to Ebola Outbreak Relief Efforts in Central Africa
- Danaher (DHR) Completes $9.9B Acquisition of Masimo Corporation
- Is Danaher (DHR) One of the Best Non-Tech Stocks to Buy According to Analysts?
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $464.01 | $326.81 | -30% |
| WuXi AppTec Co WUXAY | $18.59 | $25.09 | +35% |
| IDEXX Laboratories, Inc IDXX | $562.16 | $190.95 | -66% |
| Lonza Group LZAGY | $61.97 | $14.23 | -77% |
| Agilent Technologies, Inc A | $138.37 | $65.93 | -52% |
| Waters Corporation WAT | $357.20 | $121.96 | -66% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Danaher Corporation (DHR) undervalued?
What is the fair value of DHR?
What is the quality score of DHR?
What is the revenue of Danaher Corporation (DHR)?
What is the net profit margin of DHR?
Does Danaher Corporation pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.